GlobalResearch and clinical trials
Subcutaneous efgartigimod showed no added benefit over corticosteroids in pemphigus in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The trial included 222 adults with moderate-to-severe pemphigus. All received corticosteroids. One group also received a weekly injection. At 30 weeks, the rate of complete remission on a low corticosteroid dose was 35.5% versus 30.3%. This difference was not significant. The drug lowered antibodies in the blood but did not improve the skin findings.
What does it mean for patients and families?
This is a negative result. This drug is not recommended for pemphigus. Continue your current treatment plan with your doctor.
Source
Scientific paper: Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial. The British Journal of Dermatology, 2026. DOI: 10.1093/bjd/ljag199 · PubMed 42723554
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Pemphigus vulgaris
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.